Personal information

Countries

Spain

Activities

Collapse all

Works (9)

Data from Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy

2024-11-08 | Preprint
DOI: 10.1158/1078-0432.c.7531355
Contributors: Marta Casarrubios; Alberto Cruz-Bermúdez; Ernest Nadal; Amelia Insa; María del Rosario García Campelo; Martín Lázaro; Manuel Dómine; Margarita Majem; Delvys Rodríguez-Abreu; Alex Martínez-Martí et al.
Source: check_circle
Crossref

Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy

Journal for ImmunoTherapy of Cancer
2022-09 | Journal article
DOI: 10.1136/jitc-2022-005320
Contributors: Marta Casarrubios; Mariano Provencio; Ernest Nadal; Amelia Insa; María del Rosario García-Campelo; Martín Lázaro-Quintela; Manuel Dómine; Margarita Majem; Delvys Rodriguez-Abreu; Alex Martinez-Marti et al.
Source: check_circle
Crossref

Pro-inflammatory tumour profile predicts complete pathological response to neoadjuvant chemoimmunotherapy

2022-05-25 | Conference paper
DOI: 10.55788/31c26acb
Contributors: Marta Casarrubios; Marten Dooper; Stefan Rauh; Laura Moliner; Anne-Claire Toffart
Source: check_circle
Crossref

Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy

Clinical Cancer Research
2021-11-01 | Journal article
DOI: 10.1158/1078-0432.ccr-21-1200
Part of ISSN: 1078-0432
Part of ISSN: 1557-3265
Source: Self-asserted source
Marta Casarrubios García
grade
Preferred source (of 2)‎

KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor

ESMO Open
2021-10 | Journal article
DOI: 10.1016/j.esmoop.2021.100279
Part of ISSN: 2059-7029
Source: Self-asserted source
Marta Casarrubios García

Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial

Journal for ImmunoTherapy of Cancer
2021-08 | Journal article
DOI: 10.1136/jitc-2021-002804
Part of ISSN: 2051-1426
Source: Self-asserted source
Marta Casarrubios García

Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial

Clinical and Translational Medicine
2021-07 | Journal article
DOI: 10.1002/ctm2.491
Part of ISSN: 2001-1326
Part of ISSN: 2001-1326
Source: Self-asserted source
Marta Casarrubios García

The Role of Metabolism in Tumor Immune Evasion: Novel Approaches to Improve Immunotherapy

Biomedicines
2021-03-31 | Journal article
DOI: 10.3390/biomedicines9040361
Part of ISSN: 2227-9059
Source: Self-asserted source
Marta Casarrubios García

Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial.

The Lancet. Oncology
2020-09-24 | Journal article
DOI: 10.1016/s1470-2045(20)30453-8
PMID: 32979984
Source: Self-asserted source
Marta Casarrubios García
grade
Preferred source (of 2)‎
How many people are using ORCID?